# venBio Partners LLC: Form 13F holdings

An institutional investment manager in SAN FRANCISCO, CA. SEC CIK 1776382.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $519.4m
- Positions: 7 (7 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1776382/000090514826003741/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| PHARVARIS N V | COM | $160.6m | 30.9% | 4,643,430 |  | Added +4,126 |
| [PARABILIS MEDICINES INC (PBLS)](/companies/pbls.md) | COM | $144.1m | 27.8% | 5,266,697 |  | New +5,266,697 |
| [ALUMIS INC (ALMS)](/companies/alms.md) | COM | $127.4m | 24.5% | 4,528,408 |  | Unchanged |
| [ACHIEVE LIFE SCIENCE INC (ACHV)](/companies/achv.md) | COM | $38.6m | 7.4% | 5,914,720 |  | New +5,914,720 |
| [ALX ONCOLOGY HLDGS INC (ALXO)](/companies/alxo.md) | COM | $26.7m | 5.1% | 12,884,638 |  | Unchanged |
| [HARMONY BIOSCIENCES HLDGS IN (HRMY)](/companies/hrmy.md) | COM | $17.2m | 3.3% | 472,194 |  | Reduced −17,000 |
| [LYELL IMMUNOPHARMA INC (LYEL)](/companies/lyel.md) | COM NEW | $4.7m | 0.9% | 337,697 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [ARTIVA BIOTHERAPEUTICS INC (ARTV)](/companies/artv.md) | COM | $0 | 0.0% | 0 |  | Sold out −531,337 |

Source: SEC EDGAR, Form 13F-HR, accession 0000905148-26-003741. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.